A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer. (19th May 2018)

• Record Type: Journal Article
• Authors: Loizzi, Vera; Del Vecchio, Vittoria; Crupano, Francesco M.; Minicucci, Valentina; Fumarulo, Valeria V.; Resta, Leonardo; Vimercati, Antonella; Bettocchi, Stefano; Cicinelli, Ettore; Cormio, Gennaro
• Is Part Of: Journal of chemotherapy. Volume 30:Number 4(2018)
• Page Start: 247
• Page End: 252
• Publication Date: 2018-05-19
• Subjects: Cervical cancer -- Neoadjuvant -- Chemotherapy -- Toxicity; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2018.1489601
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : This study evaluates the efficacy and toxicity of dose-dense weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in locally advanced cervical cancer (LACC). We collected 23 cases of LACC treated with weekly paclitaxel and carboplatin for nine cycles: 20 patients had complete or partial response to chemotherapy and were submitted to surgery, 3 with poor response received chemoradiation therapy. Pathologic examination showed complete response in four patients, myometrial invasion <50% in nine and >50% in seven patients, parametrial involvement in two, vaginal metastasis in one and lymphovascular space invasion, with positive margins, in another case. Despite seven patients had radiological evidence of lymph nodes involvement at diagnosis, only one had nodal metastases. Five patients showed grade 3–4 of hematologic toxicity.